Participants whose baseline tumors harbored higher versus lower levels of PD-L1 expression on tumor-infiltrating immune cells (ICs) experienced longer OS when treated with GemCis (median OS = 27.89 versus 12.81 months) but not with GemCarbo (median OS = 14.00 versus 13.01 months; Figure 1C). This evidence concerns the gene CD274 and neoplasm.